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Abstract 
Purpose: To characterize vancomycin pharmacokinetic properties in a Jordanian population and 
identify patients’ characteristics that influence vancomycin disposition.  
Method: A non-linear mixed-effects modeling was applied to evaluate vancomycin population 
pharmacokinetic parameters in Jordanian patients using NONMEM software. Vancomycin 
concentrations were obtained retrospectively from patients’ medical records. Demographic, clinical, 
medication-related, and medical history data were collected and examined as potential predictors of 
vancomycin disposition.  
Results: A total of 164 plasma vancomycin measurements from 110 patients, including neonates, older 
children and adults were collected. Vancomycin pharmacokinetics was described using a one-
compartment model. Based on NONMEM objective function value, the selection of other models (e.g., 
two or three compartments) did not improve the performance of the pharmacokinetic model. Identified 
predictors of vancomycin clearance include: weight, serum creatinine, chronic renal failure, acute kidney 
injury and gender. Vancomycin volume of distribution was associated with weight and n-acetylcystine 
administration.  
Conclusion: The present analysis is a preliminary step toward developing a vancomycin dosing 
algorithm in Jordanian population.  
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Since its introduction in the late 1950s, 
vancomycin pharmacokinetic characteristics 
have been investigated extensively [1,2]. This 
could be attributed to the fact that vancomycin is 
associated with serious side effects. Elevated 
peak vancomycin concentrations (> 80 μg/mL) 
have been associated with increased incidence 
of ototoxicity [3,4]. Additionally, the incidence of 
nephrotoxicity increases as vancomycin steady-
state trough concentrations exceeds 15 μg/mL 
[5,6]. 
 
These side effects can be minimized by 
appropriate selection of vancomycin dose and 
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dosing interval. Appropriate therapeutic drug 
monitoring plans need to be individualized based 
on patient’s characteristics. In order to achieve 
appropriate vancomycin dosing regimens and 
monitoring, investigation of vancomycin 
pharmacokinetic properties becomes necessary. 
 
Vancomycin pharmacokinetic properties have 
been explored in several populations, including 
Malaysian [7], Japanese [8], Saudi [9], and Thai 
[10] patients. These studies were inconsistent in 
terms of population explored and analysis. For 
example, Lo et al described vancomycin 
pharmacokinetics in Malaysian neonates [7]. 
Other research groups explored adults [8-10] 
while Al-Kofide et al explored Vancomycin in a 
subgroup of Saudi adults, namely cancer 
patients. Furthermore, vancomycin 
pharmacokinetics was described using one 
compartment model in Malysian and Saudi 
patients compared to two compartment in 
Japanese and Thai patients [7-10]. Extrapolation 
of the findings of these studies to Jordanians is 
confounded by the aforementioned 
inconsistencies in the design and analysis of 
vancomycin pharmacokinetics. Hence, there is a 
knowledge gap in terms of vancomycin 
pharmacokinetics in Jordanian population. The 
objective of the present analysis is to 
characterize vancomycin pharmacokinetic 
properties in Jordanian population and identify 
patients’ characteristics that influence 
vancomycin disposition. This will enable the 
development of vancomycin dosing algorithms 
and minimize the risk of vancomycin-related 




IRB approval to review medical records of human 
patients was obtained through the medical ethics 
committee at Jordan Hospital (dated 26th, 
September 2012 with a study title of Population 
Pharmacokinetics of Vancomycin in Jordanian 
Patients). The study was conducted according to 
ICH-GCP guidelines that are consistent with the 
Declaration of Helsinki [11,12]. Routine clinical 
data were retrospectively collected from 110 
patients who received vancomycin therapy and 
had at least one recorded vancomycin 
measurement. Patients were treated at Jordan 
Hospital (Amman, Jordan) between January 
2011 and December 2012. The collected data 
were as follows: (1) demographic data (age, sex, 
height, and total weight); (2) clinical data 
(indication for vancomycin use, mechanical 
ventilation status, nutritional support, and 
laboratory data [e.g., serum creatinine; ALT and 
AST levels; biliurubin level;  blood urea nitrogen; 
fluid balance; and albumin levels]); (3) 
medication history (dosage regimen of 
vancomycin, concomitant medications, date and 
time of administration, sampling time of 
vancomycin); and (4) medical history. Several 
measurements of serum creatinine (and 
creatinine clearance) were obtained for several 
patients. The value of serum creatinine or 
creatinine clearance used in the model was 
obtained using linear interpolation. 
 
A total of 164 vancomycin measurements were 
included in the analysis. An average of 1.5 
measurements were recorded from each patient 
(range 1-5 measurements/patient),. 
Measurement of serum vancomycin 
concentrations was conducted as part of 
therapeutic drug monitoring activity in the 
hospital using the fluorescence polarization 
immunoassay (FPIA) method with Axsym system 
(package insert, Axsym system, Abbot 
Laboratories, Abbot Park, Ill, USA). 
 
Pharmacokinetic analysis  
 
Pharmacokinetic model development and 
covariate screening was conducted using 
NONMEM 6 (ICON Development Solutions, 
Ellicott City, MD). FOCE estimation option with 
three or more significant digits was used. Models 
with unsuccessful minimization were excluded 
and were not carried forward. Additionally, model 
selection was based on, a significant (p < 0.05) 
decrease in objective function (>3.84), visual 
evaluation of goodness of fit plots. These plots 
include: observed concentrations against 
individual predicted concentrations, observed 
concentrations against population predicted 
concentrations, weighted residual(using 
individual and population predictions) over time), 
parameter estimates precision (i.e. standard 
error of the mean), and changes in between-
subject and residual variability. 
 
Pharmacokinetic model development 
 
Several pharmacokinetic models (1, 2 and 3 
compartment models) were examined. A log-
normal distribution was used to describe 
between-subject variability: )exp( ki kiP  , 
where Pi is the estimated pharmacokinetic 
parameter for the ith subject, θk is the average 
population value of parameter k, and ηki is the 
inter-individual random effect for the ith subject 
and the kth parameter. Clearance (CL) and 
volume of distribution (Vd) were estimated as 
primary parameters. 
 
The residual error of the data was assumed to be 
proportional to the measured concentration 
(proportional error). Correlations between 
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estimated pharmacokinetic parameters were 
examined using visual inspection of estimated 
random effects (η) of pharmacokinetic 
parameters. 
 
Covariate analysis  
 
The correlation between pharmacokinetic 
parameters and several potential covariates, 
from clinical or biological view, with was 
examined using covariate screening. Covariate 
screening was performed using forward addition 
with subsequent backward elimination 
procedure. First, vancomycin measurements was 
modeled using the basic structural model 
described (i.e., one, two or three compartments) 
without including patients’ characteristics as 
covariates. Second, each patient’s characteristic 
was included in the mixed-effects model 
separately. Third, patients’ characteristics that 
resulted in a significant drop in NONMEM 
objective function were added simultaneously to 
the mixed effects model. Finally, step 3 was 
repeated for several iterations. In each iteration 
one covariate was excluded. The covariates that 
did not result in significant increase (compared to 
the model with all significant covariates) in 
NONMEM objective function were excluded from 
the final model. Significant change in NONMEM 
objective functions was defined, as a change of 
more than 3.84 is equivalent to a p-value of less 
than 0.05. The selection of a cut-point of 3.84 
was based on the previous finding that change in 
the objective function is equivalent to the change 
in twice the negative log-likelihood function. 
Hence, chi-square distribution (degree of 
freedom = 1) is commonly used as an 
approximation of the change in NONMEM 




Accuracy of estimated pharmacokinetic 
parameters was examined using bootstrap 
analysis. Ninety-fifth percentile confidence 
interval was estimated for all parameters. 
Resampling with replacement of the original 
dataset was used to generate 1000 simulated 
datasets. Pharmacokinetic parameters were 
estimated, using NONMEM, for each simulated 
datasets. This resulted in 1000 estimate of each 
pharmacokinetic parameter. These estimates 
were then used to calculate 95th percentile 
confidence interval 
 
The model predictive performance was examined 
using standardized visual predictive check 
(SVPC) as described by Wang [15]. One 
thousand datasets were simulated using the 
estimated pharmacokinetic parameters, 
estimated between-subject variability, and 
estimated residual variability. The simulated 
datasets are identical to the original dataset in 
terms of number of individuals, dose 
administered, and vancomycin sampling time-
points). NONMEM was used to simulate these 
datasets using the same variance model used in 
the final pharmacokinetic model (i.e. lognormal 
distribution for inter-individual variability and 
proportional error for residual variability). The 
percentile of each observation was then plotted 
vs. time. The percentile ( ijP ) of jth observation for 















kijijP   ………………… (1)   
 
where 01  ij,kij,kijij,k se, δ , otherwiy  if yδ , ijy is 
the actual jth measured vancomycin 
concentration for the ith subject, and ij,ky  is the 




The age ranged between 14 days to 88 years 
with an average of 46.1 years (standard 
deviation, 25.6). About one third (34 %) of the 
explored subjects were females. The average 
total body weight was 63.5 kg (range: 1.3 to 115 
kg). Even though this study was retrospective, 
we were able to obtain medical history 
information from patients' medical files. 
Regarding the medical history, 17% presented 
with heart failure, 18 % presented with chronic 
renal failure, 36 % experienced septic shock 
during the study, and 45 % developed acute 
kidney injury during the study.  
 
One compartment model was selected as 
structural model.  The addition of more 
compartments (i.e. distribution compartments) 
did not result in significant (p<0.05) improvement 
in the model performance (according to 
NONMEM objective function). Between-subject 
variability modeled for clearance.  
 
Identified predictors of vancomycin clearance 
include: weight (WT), serum creatinine, chronic 
renal failure (CRF), acute kidney injury (AKI), and 
gender. Vancomycin volume of distribution was 
associated with weight and n-acetylcystine 
administration. Equations 2 and 3 presents 
proposed regression equations that quantify the 
contribution of various patients’ characteristics 
and pharmacokinetic parameters. Regression 
coefficients are summarized in Table 1. 
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Gender*4+AKI*3+CRF*2+log(WT)*1+)log(Cl log(CL) 0 
……. (2) 
 
where β1, β2, β3, and β4 are parameters that 
quantify the contribution of weight, CRF, AKI and 
gender on vancomycin clearance. 
 
NAC*6+log(WT)*5+)log(V log(V) 0 
……….(3) 
 
where β5 and β6 are parameters that describe 
the influence of weight and n-acetylcystine (NAC) 
administration on vancomycin volume of 
distribution. 
 
The goodness of fit plots are presented in 
Figures 1, Figure 2 and Figure 3. Population 
predicted concentrations (PRED) and individual 
predicted concentrations (IPRED) provide 
unbiased estimates of observed vancomycin 
concentrations (Figure 1).  Weighted residuals 
for population (WRES, Figure 2) and individual 
(IWRES, Figure 3) were randomly scattered 
around 0 with no apparent trend. This finding 
was consistent over time. A good predictive 
performance of the model can be inferred from 
SVPC plot (Figure 3). Percentiles of observed 
vancomycin concentrations relative to SVPC 
simulated concentrations were evenly distributed 
between 0 and 1. The diagnostic plots 
demonstrate the adequacy of the model and 




A pharmacokinetic model was developed to 
describe the longitudinal change in vancomycin 
concentrations. Furthermore, several predictors 
of vancomycin clearance and/or volume of 
distribution were identified. A one-compartment 
model was selected. Identified predictors of 
vancomycin clearance include: weight, serum 
creatinine, chronic renal failure, acute kidney 
injury, and gender. Vancomycin volume of 




Figure 1: Observed versus individual predicted 
(upper) and population predicted (lower) 
concentrations of vancomycin 
 
Table 1: Estimated pharmacokinetic parameters for vancomycin population pharmacokinetic model 
 
Parameter Description Typical population estimate (bootstrap95% CI)* 
Cl, L/hr Clearance 0.046 (0.02, 0.08) 
Cl-IIV  Inter individual variability in clearance values 42.8% (8%,56%) 
V, L Volume of distribution 0.867 (0.48, 3.07) 
β1, 1/kg The influence of weight (Wt) on clearance 0.979 (0.84, 1.16) 
β2, dL/mg The influence of serum creatinine on clearance -0.333 (-0.98, -0.31) 
β3 The influence of chronic renal failure on clearance -1.960 (-3.55, -0.91) 
β4 The influence of acute kidney injury on clearance -0.645 (-0.93, -0.03) 
β5 The influence of gender on clearance 0.366(0.06, 0.66) 
β6 The influence of weight on volume of distribution 0.986 (0.69, 1.13) 
β7 The influence of n-acetyl cystine on volume of distribution 0.927 (0.53, 1.31) 
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Figure 3: Standardized visual predictive check (SVPC) plot for vancomycin population pharmacokinetic model 
 
Most of the variables identified by the present 
analysis are in line with previous reports. For 
example, several independent research groups 
reported that weight [16,17], serum creatinine 
[18], acute kidney injury [19], chronic renal failure 
affected vancomycin clearance and/or volume of 
distribution. 
 
Vancomycin is primarily (≥ 90%) eliminated 
unchanged in the urine by glomerular filtration 
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[3]. In addition of renal clearance, non-renal 
clearance of vancomycin is reduced in patients 
with acute or chronic renal failure [19-21]. Hence, 
it is expected for serum creatinine level to play a 
key role in predicting vancomycin clearance. 
Increased serum creatinine level is a marker of 
reduced kidney function and as a result 
decreased vancomycin clearance. Decreased 
vancomycin clearance is an obvious 
consequence of chronic renal failure [21]. 
Previous reports have demonstrated that 
vancomycin half-life is prolonged in patients with 
renal failure with no apparent change in the 
volume of distribution. Similarly, more extensive 
vancomycin accumulation is expected in patients 
with acute kidney injury [19]. 
 
Being male is associated with increased value of 
creatinine clearance. Gender affects vancomycin 
clearance as a direct consequence of its 
influence on creatinine clearance. In other words, 
adult males have higher creatinine clearance 
compared to adult females of the same age, 
weight, and serum creatinine values [22]. 
 
This is the first report of association between N-
acetylcystine administration and vancomycin 
pharmacokinetics. Previous study reported 
decreased vancomycin-associated ototoxicity 
risk as a result of N-acetylcystine use [23]. Based 
on the present findings, a speculative 
explanation for the protective effect of N-
acetylcystine is that N-acetylcystine increases 
the volume of distribution of vancomycin. As a 
result, vancomycin concentrations are expected 
to be lower in patients who received N-
acetylcystine. Hence, the incidence of ototoxicity 
is expected to be lower [24]. On the other hand, 
in the investigated cohort, 7 patients received N-
acetylcystine. The present finding cannot be 
extrapolated to a larger population without further 
investigation. 
 
The present analysis offers several advantages. 
First, it is the first population pharmacokinetic 
analysis of vancomycin in Jordanian population 
that included a wide age range (14 days - 88 
years). All patients received vancomycin as 
intravenous infusion. The change in 
pharmacokinetic parameters with age was 
accounted for in the model using body weight as 
covariate for both volume of distribution and 
clearance. Hence, adult patients are expected to 
have larger body weight compared to paediatric 
patient. According to the model, this will result in 
larger volume of distribution and clearance. 
Badran et al explored vancomycin 
pharmacokinetics in neonates admitted to the 
Jordan University Hospital [25]. However, they 
did not use population pharmacokinetics 
approach that has the ability of explaining 
variability observed among patients using 
patients’ characteristics [26-28]. Additionally, the 
previously explored cohort did not include adults. 
Furthermore, the present methodology explicitly 
accounts for changing kidney function measures. 
This was implemented using linear interpolation 
of serum creatinine values. This is valuable in 
case where patients experience acute kidney 
injury during the study. In this case, using serum 
creatinine values at the beginning failed to 
account for the decreasing kidney function that 
was observed at later time points. 
 
Limitations of the study 
 
Perhaps the main limitation of the present 
analysis is that it is a retrospective analysis. 
Hence, the investigators did not control the study 
design. For example, dose and sampling time 
points selection were based on the decision of 
the attending physician. Selecting sampling time 
points and number is important in capturing more 
extensive pharmacokinetic characteristics such 
as vancomycin tissue distribution. This explains 
the failure in selecting a more complicated 
pharmacokinetic model such as two 




A population pharmacokinetic model of 
vancomycin in Jordanian population has been 
presented in this manuscript. Additionally, 
several patient characteristics have been 
identified as predictors of vancomycin 
pharmacokinetic characteristics. The present 
analysis is a preliminary step toward developing 
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